Zoetis (ZTS)
(Delayed Data from NYSE)
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.
Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake
by Zacks Equity Research
Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Zoetis Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Zoetis has been struggling lately, but the selling pressure may be coming to an end soon.
Zoetis (ZTS) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Zoetis (ZTS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Can Zoetis (ZTS) Stock Continue to Grow Earnings?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Zoetis (ZTS).
Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the third quarter of 2018. The company also updates its 2018 outlook.
Zoetis (ZTS) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 7.79% and 1.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Zoetis beats earnings and sales estimates in the third quarter of 2018.
Should You Buy Zoetis (ZTS) Ahead of Earnings?
by Zacks Equity Research
Zoetis (ZTS) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Zoetis (ZTS) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis' (ZTS) diversified product portfolio, global footprint and productive R&D should help drive both top-and bottom-line growth in the third quarter of 2018.
Why the Earnings Surprise Streak Could Continue for Zoetis (ZTS)
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Research Reports for Pfizer, Caterpillar & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Pfizer (PFE), Caterpillar (CAT) and Charter Communications (CHTR).
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
by Zacks Equity Research
Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Coca-Cola, Disney, BHP and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Coca-Cola, Disney, BHP and Zoetis
Top Analyst Reports for Berkshire Hathaway, Coca-Cola & Disney
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Coca-Cola (KO) and Disney (DIS).
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View
by Zacks Equity Research
Zoetis second-quarter 2018 results exceed both earnings and sales estimates. The company completes the acquisition of Abaxis, Inc.
Zoetis (ZTS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 8.45% and 2.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More
by Zacks Equity Research
Let's see how these pharma/biotech stocks are poised ahead of their scheduled results on Aug 2.